mpMRI before biopsy does make sense!

/
mpMRI before biopsy does make sense!

This prospective randomized multicenter trial shows the benefits of performing mpMRI of the prostate as a first step in the management of biopsy naïve patients with clinically suspected prostate cancer.

Kasivisvanathan V. and PRECISION Study Group Collaborators. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018 Mar 18. doi: 10.1056/NEJMoa1801993. [Epub ahead of print] PubMed PMID: 29552975.

Read More

Two-sequence MR: Enough to detect csPCa?

/
Two-sequence MR: Enough to detect csPCa?

This retrospective evaluation shows no difference in diagnostic accuracy between a short 2-sequence MR protocol (T2ax + DWI) and a full mpMRI of the prostate for detection of clinically significant prostate cancer. 

Kuhl CK, Bruhn R, Krämer N, Nebelung S, Heidenreich A, Schrading S. Abbreviated Biparametric Prostate MR Imaging in Men with Elevated Prostate-specific Antigen. Radiology. 2017 Jul 20:170129. doi: 10.1148/radiol.2017170129. [Epub ahead of print] PubMed PMID: 28727544.

Read More

Conspicuity of prostate cancer lesions diminished by Dutasteride

/
Conspicuity of prostate cancer lesions diminished by Dutasteride

This prospective, randomised dual-blind study showed an increase in ADC and a decrease in conspicuity of prostate cancer lesions in men undergoing therapy with dutasteride. 

Giganti F, Moore CM, Robertson NL, McCartan N, Jameson C, Bott SRJ, Winkler M, Gambarota G, Whitcher B, Castro R, Emberton M, Allen C, Kirkham A. MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trial. Eur Radiol. 2017 May 18. doi: 10.1007/s00330-017-4858-0. [Epub
ahead of print] PubMed PMID: 28523355

Read More